Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: David Lenigas answers investor questions in a detailed interview about UKOG, Doriemus, LGC Capital, AfriAg and Angus Energy.


Scancell Holdings Share Chat (SCLP)



Share Price: 13.625Bid: 13.50Ask: 13.75Change: -0.375 (-2.68%)Faller - Scancell Hldgs
Spread: 0.25Spread as %: 1.85%Open: 14.00High: 14.00Low: 13.625Yesterday’s Close: 14.00


Share Discussion for Scancell Holdings


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


Oldnotwise
Posts: 5,093
Observation
Opinion:Hold
Price:13.625
Looks like
Today 08:48
A bit of softening on the bid.
ATB
 
CHELSEA7
Posts: 28,639
Premium Chat Member
Off Topic
Opinion:Buy
Price:13.875
NEX
Today 08:32
Latest Trades
Date & Time Volume Price
23/10/2017 08:18 15,977 13.9 Buy
23/10/2017 08:00 15,000 13.75 Sell

Volume 60,977..................sells 45k...............buys 15.977k
CHELSEA7
Posts: 28,639
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:14.00
Omeprozole-----Off Topic
Today 07:14
Thought i would post this up. This is just one of thirteen drugs i take daily. Very hard isolating which drugs cause certain side effects, but pretty sure there might be a few here on this particular drug, taken mostly for acid reflux and other gastric problems.

http://www.theessenceoflife.in/omeprazole-gastric-protector-ends-health/

Intake Of This drug Leads To Anemia, Anxiety, Depression ...
www.theessenceoflife.in
Intake Of This drug Leads To Anemia, Anxiety, Depression and Many Other Problems : OMEPRAZOLE The Gastric Protector That Ends Your Health

Hope this helps, i have stopped taking mine.
CHELSEA7
Posts: 28,639
Premium Chat Member
Off Topic
Opinion:Buy
Price:14.00
OXT RNS
Today 07:06
Portfolio Review
The companies within the portfolio continue to develop.

Select Technology, a photocopier (or more generally Multi Function Device, or MFD) software company, remains the largest holding in your Company's portfolio. The company is profitable and continues to grow, despite the continued execution of a planned transition to reduce dependency on one particular supplier, which will have the effect of increasing business resilience. Taking these developments into account, we have reverted to a valuation methodology based on a sales multiple to more appropriately reflect the prospects of the business, although the impact of this is small during the half year period.

Scancell has a strong novel cancer related clinical development pipeline. SCIB1, targeting malignant melanoma, has had good Phase1/2 results and a Phase 2 combination trial with an immune checkpoint inhibitor is planned for 2018. SCIB2 targets non-small lung cancer and Modi-1 targets breast and ovarian cancers and osteosarcoma. Four Phase 1/2 trials on each target are also planned for 2018. Scancell raised £5 million at 10p per share during the reporting period in an oversubscribed AIM placing - your company did not take part in this due to restrictive VCT rules. The net proceeds of the placing (£4.7 million after expenses) are being used to support the Company's clinical development pipeline of novel cancer immunotherapies and to continue to support the pipeline arising from the ImmunoBody platform.

The bid price of Scancell's shares used for the calculation of the Company's net asset value on 31 August 2017 was 14.0p, unchanged from the bid price on 28 February 2017.

The Directors along with the Investment Advisor continue to take an active interest in the remaining companies within the portfolio, both to support their management teams to achieve company development, but also to prepare companies for realisation at the appropriate time. It should be noted that the current portfolio is highly concentrated with Select representing 51% and Scancell 35% of the VCT's equity - your Company's NAV is therefore very sensitive to changes in the valuations of these two portfolio companies.

https://www.investegate.co.uk/oxford-technology--oxt-/gnw/oxford-technology-vct-plc---half-year-report/20171023070018H3041/
CHELSEA7
Posts: 28,639
Premium Chat Member
Off Topic
Opinion:Buy
Price:14.00
RE: Cost of cancer drugs
Today 06:07
Morning All, and it has been a major factor in all the years that i have been here. Will it ever have some form of compromise. This piece from the article screams for a solution, what about the human cost??....................

Emma Robertson, 35, has incurable breast cancer and is taking the drug, palbociclib.
This drug was originally developed using work carried out by publicly funded Cancer Research UK scientists in the 1980s, for which they won the 2001 Nobel Prize.
In February, the National Institute of Health and Care Excellence (Nice) made a provisional decision not to recommend the drug because the cost was too high in relation to its potential benefits.
However Ms Robertson is receiving the drug through a free trial provided by the drug company Pfizer.
A full course of treatment with palbociclib costs £79,650, which campaigners say means the manufacturer is vastly overpricing the drug.
They claim it could be made and sold for a profit for £1 per pill, but say in fact it is currently sold for 140 times more.
"Pfizer needs to dramatically reduce the price that it wants to charge for this drug," Ms Robertson says.
"We need to be asking some really serious questions about how drugs are researched and developed," she adds.
ratcliffewriter
Posts: 7,403
Observation
Opinion:Strong Buy
Price:14.00
Cost of cancer drugs
Sun 22:38
..continues to be a major factor -

Taxpayer-funded drugs 'too expensive for patients£ - http://www.bbc.co.uk/news/health-41693246
ratcliffewriter
Posts: 7,403
Observation
Opinion:Strong Buy
Price:14.00
View Thread (5)
RE: Ratty.
Sun 09:25
Bl00dy hell aggie! That's a textbook ramp if ever there was.
crumbs
Posts: 11,318
Off Topic
Opinion:No Opinion
Price:14.00
View Thread (2)
RE: Ratty.
Sun 09:16
Comedy gold....
agema
Posts: 3,647
Off Topic
Opinion:No Opinion
Price:14.00
Ratty.
Sun 09:01
I never ramp. Unlike most. I don£t ever feel the need to.

Links are old news. Links means the sp has already gone.

At times I get good vibes. They are very rarely wrong. Merl and pfc are very well priced. Very nice rises will come on them two for Definate. Now is the right time to buy them.

Going to the states for three weeks on Monday. While there going on a horror night. Guess I£ll see you there. Gotta go, a lot to do today.
ratcliffewriter
Posts: 7,403
Observation
Opinion:Strong Buy
Price:14.00
View Thread (3)
RE: Hi c7
Sun 08:05
Have you got a link to back that up aggie? Or is it just another of your pathetic ramps?




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.